Brain Microvascular Endothelial Cell Differentiation Protocol
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for differentiating human pluripotent stem cells into brain microvascular endothelial cells (BMECs) use undefined culture systems, leading to line-to-line variability and are not suited for clinical applications or large-scale production, as they fail to provide a renewable source of functional BMECs under chemically defined conditions.
Innovation Solution
A method involving culturing human pluripotent stem cells in a chemically defined, serum-free medium with activators of Wnt/β-catenin signaling, followed by B27 supplement and retinoic acid, to obtain a population of BMECs that express specific markers like CD31+, P-glycoprotein+, and claudin-5+, achieving a high purity and functional integrity similar to primary BMECs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If undefined culture systems are used for differentiating human pluripotent stem cells to BMECs, then the differentiation process can be performed, but line-to-line variability occurs and the method is not suited for clinical applications
Solution Approach 1:
The patent applies parameter changes by transitioning from undefined culture systems to fully chemically defined culture media with specified compositions. The differentiation protocol uses precisely controlled concentrations of signaling molecules (Wnt agonists at 3-12 μM, retinoic acid at 1-10 μM, bFGF at 1-20 ng/mL) and defined supplements (B27, N2, ITS) to eliminate batch-to-batch and line-to-line variability while maintaining ease of manufacture through standardized reagent formulations.
2Reliability
If chemically defined culture conditions are implemented, then reliability and scalability for clinical applications are improved, but the complexity of the differentiation protocol increases
Solution Approach 1:
The patent segments the differentiation protocol into three distinct sequential stages, each with specific chemically defined media compositions and signaling molecule combinations. Stage 1 uses Wnt agonists to induce mesoderm, Stage 2 adds retinoic acid for endothelial progenitor specification, and Stage 3 incorporates bFGF and other factors for BMEC maturation. This segmentation simplifies the overall complexity by breaking down the complex differentiation process into manageable, standardized steps that can be independently optimized and replicated.
3Manufacturing precision
If existing differentiation methods are used, then BMEC generation is possible, but the purity and functional integrity of the resulting BMEC population is insufficient
Solution Approach 1:
The patent incorporates feedback mechanisms through the use of stage-specific signaling molecules that respond to and reinforce the differentiation state. Wnt agonists provide feedback to maintain mesodermal commitment, retinoic acid provides feedback for endothelial specification, and bFGF provides feedback for BMEC maturation and functional integrity. This feedback system ensures high purity (>90% BMEC purity by flow cytometry) and functional integrity (physiologic TEER values, efflux transporter activity) while maintaining efficient differentiation rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method generates a population of BMECs with physiologic transendothelial electrical resistance and efflux transporter activities, demonstrating key BBB phenotypes and properties, thereby providing a reliable and scalable source for clinical and research applications.
Implementation Method 1
culturing human pluripotent stem cells for about 24 hours in a chemically defined, serum-free culture medium that comprises an activator of Wnt/β-catenin signaling
Implementation Method 2
The activator of Wnt/β-catenin signaling can be a Gsk3 inhibitor. The Gsk3 inhibitor can be a small molecule selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiCl, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.
Implementation Method 3
culturing the Flk-1+ cells of (b) for about two days in the presence of a chemically defined, serum-free endothelial medium comprising B27 supplement, bFGF/FGF2, and retinoic acid (RA), whereby a cell population comprising human BMECs is obtained
Implementation Method 4
culturing the Flk-1+ cells of (b) for about two days in the presence of a chemically defined, serum-free endothelial medium comprising B27 supplement, bFGF/FGF2, and retinoic acid (RA)
Implementation Method 5
the method comprises taking an initial transendothelial electrical resistance (TEER) measurement of the confluent monolayer, where the TEER measurement is greater than 2000 Ohm (Ω)×cm2
Data Source
AI summary
Methods for generating functional brain microvascular endothelial cells (BMECs) under chemically defined, serum-free conditions are provided. In particular, efficient and cost-effective methods for generating functional BMECs under chemically defined culture conditions are provided. BMECs obtained according to the methods provided herein are suitable for in vitro blood brain barrier (BBB) formation.